Market Snapshot

Nasdaq ticker symbol:	IMNN
Stock price (11/14/2022):	$1.50
52-week range:	$1.39- $12.60
Market capitalization:	$12 mill
Officer & director ownership:	1.5%
Fiscal year-end:	Dec 31

Imunon, Inc. (Nasdaq: IMNN) is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: the **TheraPlas** modality for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and the **PLACCINE** modality for the development of nucleic acid vaccines for infectious diseases and cancer. These platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. Imunon will continue to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. In September 2022, Imunon changed its name and ticker symbol from Celsion Corporation (CLSN).

Investment Highlights

- **Leveraging innovative plasmid DNA and proprietary synthetic delivery system platforms** to create novel therapeutics with an initial clinical focus on immuno-oncology and infectious diseases. Imunon's TheraPlas technology delivers DNA and mRNA therapeutics via synthetic, non-viral carriers, while PLACCINE is being developed to deliver plasmid DNA vaccines with a delivery system offering multiple benefits versus currently available technologies. Each technology and indication are directed to large, underserved markets.
- **Later stage clinical trials** offer opportunity for value-creating catalysts. The OVATION 2 randomized Phase II trial with GEN-1 (IL-12 immunotherapy) for the localized treatment of advanced ovarian cancer is fully enrolled. Earlier studies have shown strong efficacy signals; and interim Phase II data are promising with potential for a targeted therapy in BRCA-negative patients. GEN-1 has received FDA Fast Track and Orphan designations. A second Phase II trial is planned using GEN-1 in combination with bevacizumab (Avastin)
- **PLACCINE prophylactic vaccine platform shows strong evidence of immunogenicity and durability of protection** in a SARS-CoV-2 proof-of-concept model. Non-human primate data in late 2022 are expected to bolster support for the technology. Discovery efforts in cancer vaccines are ongoing.
- **Focus on continued platform innovation** and discovery, both internally and through licensing agreements.
- **Healthy balance sheet.** Cash and access to non-dilutive capital of more than $45 million as of September 30, 2022 funds strategy into 2025, through to robust news flow of value-creating activities.
- **Highly experienced management team.** New CEO Corinne Le Goff, Pharm.D., MBA brings decades of global healthcare leadership experience across a range of therapeutic areas including oncology, vaccines and immunology and joins an existing talented team.

Two Next Generation DNA Plasmid Platform Technologies: TheraPlas and PLACCINE

Proprietary DNA plasmid platforms encoding for a variety of proteins including cytokines, enzymes, mAbs and antigens

TheraPlas

- Polymeric nanoparticle delivers DNA plasmids coding for therapeutic proteins
- Safely administered to more than 100 patients to-date

PLACCINE

- DNA plasmid vectors engineered for next-generation vaccine technology and delivered with a synthetic delivery systems free of a device or viral vector
- Designed for multiple antigens/epitopes with option for the co-expression of immunomodulators

Immuno-Oncology



Phase II localized IL-12 evaluation in advanced ovarian cancer with FDA Orphan drug designation, U.S. and EU Fast Track designation

Prophylactic & Therapeutic Vaccines



Proof-of-concept in SARS-CoV-2 to demonstrate PLACCINE as a best-in-class prophylactic vaccine platform

Clinical and Preclinical Product Pipeline

Platform	Program	Indication(s)	Discovery	IND enabling	Phase 1	Phase 2
TheraPlas	**IL-12 (OVATION)** Intraperitoneal (IP)	Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	GEN-1			
	IL-12 IP in combination with **bevacizumab**	Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	GEN-1			
PLACCINE	**Multicistronic SARS-Cov2.** Proof-of-Concept	COVID-19 Booster	PL-COV			
	Prophylactic Vaccine	Infectious Disease target	PL-X			
	Therapeutic Vaccine	Cancer target	PL-Z			

GEN-1: Lead Immuno-Oncology Program

GEN-1 Targets Ovarian Cancer Metastases Throughout the Peritoneal Cavity



Local Expression of IL-12 Favors Immune Modulation in Tumor Microenvironment

Phase I/II Open-Label Trial In Advanced Ovarian Cancer

- Enrollment completed
- 50% of expected primary endpoint data collected
- ITT population contains mix group of BRCA +/- subjects (BRCA + have much longer time to PFS due to PARPi)
- Primary Endpoint: PFS after 80 events or at least 16 months
- Secondary Endpoints: Clinical Response, Surgical Resection Score and Chemotherapy Response Score

Interim Data (50% of events)	NACT ONLY	NACT + GEN-1
Interval Debulking Surgery (n=70) R0 Resection Rate	56%	68%
Median Time to Progression (mos.) 50% of events	12.8	15.0
Chemotherapy Response Score of CRS3	17%	31%

PLACCINE Platform: Powering the Next Generation of Vaccines



Durability of Protection	Durable antigen expression induces robust immunological response
Breadth of Protection	Multicistronic vectors increase the breadth of immune response and allows for combination vaccines
Transmission Advantage	Strong T-cell activity. Option for co-expression of potent immune modifiers increases the immune response and lowers the risk of viral shedding
Safe and Convenient	Synthetic delivery systems present no risk of genotoxicity - no virus, or cytotoxicity - no device. Convenient handling for pandemic control.
Flexible Manufacturing	Truly versatile platform enables rapid response to changing pathogens. Stability and long shelf-life at normal refrigerator temperatures simplifies handling and distribution.

Near-term Milestones

- **Report final non-human primate SARS-CoV-2 results – 2H22**
- **Identify next PLACCINE pathogen target – 2H22**
- **Initiate GEN-1 Phase II combo trial with bevacizumab – 1H23**
- **File PLACCINE SARS-CoV-2 IND – 1H23**

Investor Relations Contacts

Imunon
Jeffrey W. Church, CFO
jchurch@imunon.com
(609) 896-9100
www.celsion.com

LHA
Kim Sutton Golodetz
kgolodetz@lhai.com
(212) 838-3777
www.lhai.com

The information contained herein was obtained from Imunon management and other sources LHA believes to be reliable. This does not constitute the solicitation of the purchase or sale of securities. LHA has been engaged by Imunon as its investor relations firm. Except for historical information contained herein, matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please see the most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks.

November 2022